CXCR4 Antagonist Reduced the Incidence of Acute Rejection and Controlled Cardiac Allograft Vasculopathy in a Swine Heart Transplant Model Receiving a Mycophenolate-based Immunosuppressive Regimen
Open Access
- 1 December 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 102 (12) , 2002-2011
Abstract
Background: CXC motif chemokine receptor 4 (CXCR4) blockade is pursued as an alternative to mesenchymal stem cell treatment in transplantation based on our previous report that burixafor, through CXCR4 antagonism, mobilizes immunomodulatory mesenchymal stem cells. Here, we explored the efficacy of combining mycophenolate mofetil (MMF)-based immunosuppressants with repetitive burixafor administration. Methods: Swine heterotopic cardiac allograft recipients received MMF and corticosteroids (control, n = 10) combined with burixafor as a 2-dose (burixafor2D, n = 7) or 2-dose plus booster injections (burixafor2D + B, n = 5) regimen. The efficacy endpoints were graft survival, freedom from first acute rejection, and the severity of intimal hyperplasia. Each specimen was sacrificed either at its first graft arrest or after 150 days. Results: After 150 days, all specimens in the control group had died, but 28.5% of the burixafor2D group survived, and 60% of the burixafor2D + B group survived (P = 0.0088). Although the control group demonstrated acute rejection at a median of 33.5 days, the burixafor2D + B group survived without acute rejection for a median of 136 days (P = 0.0209). Burixafor administration significantly attenuated the incidence rate of acute rejection (P = 0.002) and the severity of intimal hyperplasia (P = 0.0097) at end point relative to the controls. These findings were associated with reduced cell infiltrates in the allografts, and modulation of C-reactive protein profiles in the circulation. Conclusions: The augmentation of conventional MMF plus corticosteroids with a CXCR4 antagonist is potentially effective in improving outcomes after heart transplantation in minipigs. Future studies are warranted into optimizing the therapeutic regimens for humans.Keywords
This publication has 48 references indexed in Scilit:
- Impact of Mycophenolic Acid and Tacrolimus on Th17-Related Immune ResponseTransplantation, 2011
- SDF-1α Induction in Mature Smooth Muscle Cells by Inactivation of PTEN Is a Critical Mediator of Exacerbated Injury-Induced Neointima FormationArteriosclerosis, Thrombosis, and Vascular Biology, 2011
- Mesenchymal stem cells together with mycophenolate mofetil inhibit antigen presenting cell and T cell infiltration into allogeneic heart graftsTransplant Immunology, 2011
- Conversion From Calcineurin Inhibitor to Mycophenolate Mofetil-Based Immunosuppression Changes the Frequency and Phenotype of CD4+FOXP3+ Regulatory T CellsTransplantation, 2009
- Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolateTransplant Immunology, 2008
- Cellular Rejection of the Conduction System After Orthotopic Heart Transplantation for Congenital Atrioventricular BlockThe Journal of Heart and Lung Transplantation, 2006
- T Cell Costimulation in the Development of Cardiac Allograft VasculopathyArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- The Cumulative Effect of Acute Rejection on Development of Cardiac Allograft VasculopathyThe Journal of Heart and Lung Transplantation, 2006
- Effects of Mycophenolate Mofetil on Cardiac Allograft Survival and Cardiac Allograft Vasculopathy in Miniature SwineThe Annals of Thoracic Surgery, 2005
- Frequency and mechanism of bradycardia in cardiac transplant recipients and need for pacemakersThe American Journal of Cardiology, 1991